{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:39:33Z","timestamp":1763746773743},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T00:00:00Z","timestamp":1229558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib mesylate has proven to be the most effective treatment in chronic myeloid leukemia. Nevertheless, imatinib resistance has raised concern and prompted interest in additional strategies to achieve disease eradication. Resistance to imatinib is mainly associated with three mechanisms: acquired mutations in the kinase domain of <jats:italic>BCR\u2013ABL<\/jats:italic> protein, genetic amplification, and transcript overexpression of <jats:italic>BCR\u2013ABL<\/jats:italic> rearrangement. Therefore an accurate assessment of resistance mechanism is particularly important to improve strategies to overcome resistance. In order to determine overexpression of <jats:italic>BCR\u2013ABL<\/jats:italic>, we propose a method that correlates quantitative real time PCR and fluorescence <jats:italic>in situ<\/jats:italic> hybridization data from the same peripheral blood sample. The ratio between both methodologies permits to calculate the expression index (EI) for each patient. EI estimates the rate of <jats:italic>BCR\u2013ABL<\/jats:italic> transcription <jats:italic>per<\/jats:italic> rearrangement. The median EI value, including all cases (<jats:italic>n<\/jats:italic>\u2003=\u2003123), was 0.288; those cases (<jats:italic>n<\/jats:italic>\u2003=\u200313) included in percentile 90 showed an increment of EI above 1 Log (&gt;2.88) with respect to the median value and were considered as cases with overexpression. We also evaluated the EIs using receiver operating characteristics curve; choosing an EI cutoff of 1.836 we obtained a sensitivity of 95% and a specificity of 61%. Using this EI cutoff value, more patients (<jats:italic>n<\/jats:italic>\u2003=\u200317) were included in the overexpression group. Patients within this group were resistant to imatinib and also showed a worse overall survival if compared with the remaining.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01199.x","type":"journal-article","created":{"date-parts":[[2008,12,19]],"date-time":"2008-12-19T19:33:36Z","timestamp":1229715216000},"page":"292-300","source":"Crossref","is-referenced-by-count":14,"title":["Specific assessment of <i>BCR\u2013ABL<\/i> transcript overexpression and imatinib resistance in chronic myeloid leukemia patients"],"prefix":"10.1111","volume":"82","author":[{"given":"Michele","family":"Bianchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos De","family":"Brasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Gargallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Bengi\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,19]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1499","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907153410306"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404318"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402741"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.20.1641"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200207000-00007"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4111"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402329"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.1171"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0993-1026"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.00671.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V95.2.404","article-title":"Persistence of BCR\u2010ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon\u2010alfa therapy or allogeneic bone marrow transplantation","volume":"95","author":"Chomel JC","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2005.03.011"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07678-X"},{"key":"e_1_2_6_20_2","article-title":"Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy","volume":"98","author":"Kreil S","year":"2001","journal-title":"Blood"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00979-3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3864"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01199.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01199.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:05:48Z","timestamp":1695935148000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01199.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,19]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01199.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01199.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,19]]}}}